FDA clears Halt's electrosurgical system for RF ablation

The FDA has cleared Halt Medical’s Halt 2000GI electrosurgical system for soft tissue ablation using radiofrequency (RF) energy.

RF ablation with the Halt system is a minimally invasive procedure that inserts a probe into the target tumor under ultrasound guidance, according to the Livermore, Calif.-based company. Once in position, the system delivers energy to the tissue, generating heat that can destroy the tumor. Halt said that the procedure is an option for tumors of the liver, breast, prostate, bone and kidneys.

Around the web

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.